Inhibition of protein-protein interactions: The discovery of druglike β-catenin inhibitors by combining virtual and biophysical screening

Proteins: Structure, Function and Genetics

Volumn 64, Issue 1, 2006, Pages 60-67

  Trosset, Jean Yves ^a   Dalvit, Claudio ^a   Knapp, Stefan ^a,b   Fasolini, Marina ^a   Veronesi, Marina ^a   Mantegani, Sergio ^a   Gianellini, Laura M ^a   Catana, Cornel ^a,c   Sundström, Michael ^a,b   Stouten, Pieter F W ^a   Moll, Jürgen K ^a  

^a Nerviano Medical Sciences ^*  (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

catenin; Docking; Druglike inhibitors; Inhibition of protein protein interaction; Tcf4; Virtual screening

Indexed keywords

BETA CATENIN; PROTEIN INHIBITOR; T CELL FACTOR PROTEIN; T CELL FACTOR PROTEIN 3; T CELL FACTOR PROTEIN 4; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; BINDING AFFINITY; BINDING COMPETITION; ISOTHERMAL TITRATION CALORIMETRY; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; SCREENING; SIGNAL TRANSDUCTION; SURFACE PROPERTY;

BETA CATENIN; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HUMANS; MODELS, MOLECULAR; MUTATION; NEOPLASMS; PROTEIN CONFORMATION; PROTEINS; SOFTWARE; USER-COMPUTER INTERFACE;

EID: 33744821869     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.20955     Document Type: Article

References (33)

1. Drews J. Drug discovery: a historical perpective. Science 2000;287:1960-1964.
2. Jones S, Thornton J. Principles of protein-protein interactions. Proc Natl Acad Sci USA 1996;93:13-20.
3. Arkin ME, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov Sci 2004;3:301-317.
4. Clackson T, Wells JA. A hot spot of binding energy in a hormone-receptor interface. Science 1995;267:383-386.
5. Cochan G. Protein-protein interfaces: mimics and inhibitors. Curr Opin Chem Biol 2001;5:654-659.
6. Peczuh MW, Hamilton AD. Peptide and protein recognition by designed molecules. Chem Rev 2000;100:2479-2494.
7. Kallen J, Welzenbach K, Ramage P, Geyl D, Kriwacki K, Legge G, Cottens S, Weitz-Schmidt G, Hommel U. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol 1999;292:1-9.
8. Gadek TR, Burdick DJ, McDowell RS, Stanley MS, Marsters JC Jr, Paris KJ, Oare DA, Reynolds ME, Ladner C, Zioncheck KA, Lee WP, Gribling P, Dennis MS, Skelton NJ, Tumas DB, Clark KR, Keating SM, Beresini MH, Tilley JW, Presta LG, Bodary SC. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science 2002 295:1086-1089
9. Emerson SD, Palermo R, Liu CM, Tilley JW, Chen L, Danho W, Madison VS, Greeley DN, Ju G, Fry DC. NMR characterization of interleukin-2 in complexes with the IL-2Rα receptor component and with low molecular weight compounds that inhibit the IL-2/IL-Rα interaction. Protein Sci 2003;12:811-822.
10. Arkin MR, Randal M, DeLano WL, Hyde J, Luong TN, Oslob JD, Raphael DR, Taylor L, Wang J, McDowell RS, Wells JA, Braisted AC. Binding of small molecules to an adaptive protein-protein interface. Proc Natl Acad Sci USA 2003;100:1603-1608.
11. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-848.
12. Berg T. Modulation of protein-protein interaction with small organic molecules. Angew Chem. 2003;42:2462-2481.
13. Ocke DA, Gadek TR. Inhibitors of protein-protein interactions. Expert Opin Ther Patents 2002;12:393-400.
14. Norin M, Sundström M. Protein models in drug discovery. Curr Opin Drug Discov Dev 2001;4:284-290.
15. Graham TA, Weaver C, Mao F, Kimelman D, Xu W. Crystal structure of a β-catenin/Tcf complex. Cell 2000;103:885-896.
16. Poy F, Lepourcelet M, Shivdasani RA, Eck MJ. Structure of a human Tcf4-β-catenin complex. Nat Struct Biol 2001;12:1053-1057.
17. Abagyan R, Totrov M, Kuznetsov D. ICM-a new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation. J Comput Chem 1994;15:488-506.
18. Omer CA, Miller PJ, Diehl RE, Kral AM. Identification of Tcf4 residues involved in high-affinity β-catenin binding. Biochem Biophys Res Comm 1999;256:584-590.
19. Knapp S, Zamai M, Volpi D, Nardese V, Avanzi N, Breton J, Plyte S, Flocco M, Marconi M, Isacchi A, Caiolfa VR. Thermodynamics of the high-affinity interaction of Tcf4 with β-catenin. J Mol Biol 2001;306:1179-1189.
20. Pasolini M, Wu X, Flocco M, Trosset JY, Oppermann U, Stefan K. Hotspots in Tcf4 for the interaction with β-catenin. J Biol Chem 2003;278:21092-21098.
21. Brady GP Jr, Stouten PFW. Fast prediction and visualization of protein binding pockets with PASS. J Comput Aided Mol Des 2000;14:383-401.
22. McMartin C, Bohacek RS. QXP: powerful, rapid computer algorithms for structure-based drug design. J Comput Aided Mol Des 1997;11:333-344. QXP_FLO program: Thistlesoft, PO Box 227, Colebrook, CT 06021.
23. Shaul Y, Schreiber G. Exploring the charge space of protein-protein association: a proteomic study. Proteins 2005;60:341-352. http://bip.weizmann. ac.il/hypareb/main.
24. Schreiber G, Fersht AR. Rapid, electrostatically assisted association of proteins. Nat Struct Biol 1996;3:427-431.
25. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26.
26. Gao H, Shanmugasundaram V, Lee P. Estimation of aqueous solubility of organic compounds with QSPR approach. Pharm Res 2002;19:497-503.
27. Catana C, Gao H, Orrenius C, Stouten PFW. Linear and non-linear methods in modeling the aqueous solubility of organic compounds. J Chem Inf Model 2005;45:170-176.
28. Dalvit C, Fogliatto GP, Stewart A, Veronesi M, Stockman B. WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability. J Biomol NMR 2001;21:349-359.
29. Dalvit C, Fasolini M, Flocco M, Knapp S, Pevarello P, Veronesi M. NMR-based screening with competition water-ligand observed via gradient spectroscopy experiments: detection of high-affinity ligands. J Med Chem 2002;45:2610-2614.
30. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, Croce CM, Alnemri ES, Huang Z. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000;97:7124-7129.
31. Rector DL, Conder GA, Folz SD. Preparation of N-heterocyclylalkylidene acylhydrazones as anthelmintic agents. PCT Int Appl 1987;WO 8706127;A1;19871022.
32. Moll J, Knapp S, Dalvit C, Trosset JY, Sundstrom M, Mantegani S. Preparation of heterocyclic compounds which interact with beta-catenin/TCF-4 binding site. PCT Int Appl 2003;WO 2003006447;A2;20030123.
33. Lepourcelet M, Chen YNP, France DS, Wang H, Crews P, Petersen F, Bruseo C, Wood AW, Shivdasani RA. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell 2004;5:91-102.